A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Trial Profile

A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs F8 IL10 (Primary) ; Methotrexate; Methotrexate; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Philogen
  • Most Recent Events

    • 08 Nov 2017 Status changed from recruiting to completed, according to the results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results of phase Ib trial (NCT02076659; n=34) and the phase II trial (NCT02270632; n=23; As of May 2017), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of phase 1b (NCT02076659; n=34) and phase 2 (NCT02270632; Data cut off 22 January 2017; n=22) trials, presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top